Skip to main content

Table 3 Univariate cox proportional hazard analyses for association with RFS

From: Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

% change from baseline

Mid-treatment

Post-treatment

N

Number recurred

HRa (95% CI)

p

N

Number recurred

HRa (95% CI)

p

K1

34

7

1.03

(1.01–1.05)

< 0.01b

29

6

1.07

(1.02–1.12)

0.01

MRFDG

34

7

1.04

(1.01–1.08)

0.01b

29

6

1.13

(0.98–1.3)

0.09

SUVmax (30–60 min)

34

7

1.19

(0.98–1.45)

0.08

29

6

1.19

(0.98–1.44)

0.07

ADC

33

7

0.94

(0.81–1.08)

0.39

31

6

0.93

(0.81–1.08)

0.35

Peak PE

34

7

1.21

(0.95–1.54)

0.13

31

6

1.19

(1.01–1.39)

0.03

Peak SER

34

7

1.38

(1.03–1.84)

0.03

31

6

1.26

(1.03–1.55)

0.03

FTV

34

7

1.06

(0.94–1.2)

0.33

31

6

1.08

(1.02–1.14)

0.01

Washout volume

34

7

1.19

(1.03–1.36)

0.01b

31

6

1.09

(1.02–1.17)

0.01

Longest dimension

34

7

0.99

(0.94–1.06)

0.85

31

6

1.00

(0.96–1.05)

0.72

MRFDG/Peak PE

33

7

1.04

(1.01–1.07)

0.01b

28

6

1.00

(0.92–1.08)

0.93

MRFDG/Peak SER

33

7

1.04

(1.01–1.07)

0.01b

28

6

1.03

(0.92–1.15)

0.66

MRFDG/K1

34

7

0.98

(0.91–1.05)

0.51

29

6

1.00

(0.95–1.04)

0.87

SUVmax/peak PE

33

7

1.06

(0.93–1.21)

0.38

28

6

1.00

(0.95–1.06)

0.97

SUVmax/peak SER

33

7

1.05

(0.91–1.22)

0.47

28

6

1.03

(0.93–1.14)

0.60

  1. SUVmax maximum standardized uptake value, ADC apparent diffusion coefficient, PE percent enhancement, SER signal enhancement ratio, FTV functional tumor volume, RCB residual cancer burden
  2. a1 unit = 5% change
  3. bSignificant after adjustment for multiple comparisons
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us